



## COMPANY OVERVIEW

Amarantus BioScience Holdings, Inc. is a publicly traded biotechnology company focused on developing therapeutic products with the potential for orphan drug designation in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, and diagnostics in neurology.

## RECENT NEWS

**Amarantus Enters into Letter of Intent with The Alchemists Kitchen to Establish Joint Venture for Research and Commercialization of Hemp and Herbal Smokables for Addiction Treatment Including Smoking Cessation**

Jun 25 2019, 8:00 AM EDT

**Amarantus Announces Positive Pre-Clinical Data for MANF in Wolfram Syndrome Presented at the 79th Annual Scientific Sessions of the American Diabetes Association**

Jun 18 2019, 8:00 AM EDT

**Amarantus Announces Issuance of US Patent No. 10,195,251 Covering MANF Treatment of Wolfram's Syndrome, Retinitis Pigmentosa, and Glaucoma for Subsidiary MANF Therapeutics**

Jun 13 2019, 8:42 AM EDT

## STOCK OVERVIEW

Symbol	AMBS
Exchange	OTCPink
Shares OS	68,272,000
Market Cap	\$1.13M
Last Price	<b>\$0.016575</b>
52-Week Range	<b>\$0.01 - \$0.0765</b>
Fiscal Year End	<b>December 31</b>

09/19/2019 02:24 PM EDT

## INVESTOR RELATIONS

American Capital Ventures, Inc.  
Howard Gostfrand  
President  
T: 305-918-7000  
F: 305-468-6165  
[hg@amcapventures.com](mailto:hg@amcapventures.com)

## MANAGEMENT TEAM

**Gerald E. Commissiong**  
President & Chief Executive Officer

**Brian E. Harvey, MD, PhD**  
Chief Regulatory Advisor

**Elise Brownell, Ph.D.**  
Senior Vice President of Operations and Project Management

**John W. Commissiong, PhD**  
Chief Scientific Officer

**Paula Trzepacz, MD**  
Chief Medical Advisor to Elto Pharma and Breakthrough Diagnostics

**Dr. Richard Kagan**  
Chief Medical Advisor to Cutanogen Corporation

## AMARANTUS BIOSCIENCE HOLDINGS, INC.

45 Wall Street  
Suite 920  
New York, NY 10005  
US

## DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.